Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan Nobuaki Matsubara NPO Prostate Cancer Patients Association, Hyogo, Japan Tsutomu Takeuchi Janssen ... View author publications You can also search for this author in PubMed Google Scholar Wakako Osaka View author publications You can also search for this author in PubMed Google Scholar Nobuaki
Background Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated with docetaxel. However, data on the antitumor activity of AA as a second androgen...
Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated with docetaxel. However, data on the antitumor activity of AA as a second androgen receptor...
Nobuaki Matsubara Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea Jae-Lyun Lee Yale University, New Haven, CT, USA Daniel P. Petrylak Erasmus MC Cancer Institute ... publications You can also search for this author in PubMed Google Scholar Nobuaki Matsubara View author publications You can also search for this author in PubMed Google Scholar Jae-Lyun Lee View
Up to a fifth of patients diagnosed with prostate cancer (PC) will develop castration-resistant prostate cancer (CRPC), which has been associated with a poor prognosis. The aim of this study was to consider the patient perspective as part of the overall treatment decision-making process for CRPC, given that an alignment between patient preference and prescribing has been shown to...
Background Up to a fifth of patients diagnosed with prostate cancer (PC) will develop castration-resistant prostate cancer (CRPC), which has been associated with a poor prognosis. The aim of this study was to consider the patient perspective as part of the overall treatment decision-making process for CRPC, given that an alignment between patient preference and prescribing has...
Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa, Chiba , Japan 3 Nobuaki Matsubara 4 Clinical Pharmacology Oncology, Bayer AG , Berlin , Germany 5 Clinical Statistics , Bayer Yakuhin, Osaka , Japan ... being jointly developed with Bayer HealthCare Pharmaceuticals. Compliance with ethical standards Funding Bayer Yakuhin, Ltd. sponsored the study. Conflict of interest Nobuaki Matsubara has received
PurposeIpatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors.MethodsThis was a phase I, open-label, 3 + 3 dose-escalation study conducted in two stages. In stage I, Japanese patients with solid tumors were...
, Kashiwa, Chiba , Japan 2 Affiliation of Masanobu Yasuda should be: Clinical Statistics , Bayer Yakuhin, Osaka , Japan 3 Nobuaki Matsubara 4 Clinical Pharmacology Oncology, Bayer AG , Berlin , Germany 5
standards Conflict of interest Seigo Kinuya received lecture fees from Bayer, Japan. Yoko Yajima is an employee of Bayer Yakuhin, Ltd. Hiroji Uemura, Hirotsugu Uemura, Nobuaki Matsubara, Makoto Hosono and
received honoraria from Janssen, and research funding from Bayer, Lidds AB, and Astellas Pharma. Ken-ichi Tabata has received honoraria from Janssen. Nobuaki Matsubara has received honoraria from Chugai
Bayer. Iku Yamaguchi and Takashi Akagawa are employees of Bayer Yakuhin Ltd. Nobuaki Matsubara has received research funding from Bayer. All remaining authors declared no conflict of interest
Division of Breast and Medical Oncology, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa 277-8577 , Japan 3 Nobuaki Matsubara 4 Department of Urology, Keio University School of Medicine
Previous studies have established the rationale for NK105, a nanomicellar formulation of paclitaxel, administered every 3 weeks. The aim of this phase I study was to determine the recommended dose and pharmacokinetics of weekly administered NK105. NK105 was administered by a 30-min infusion once weekly for three consecutive weeks in each 4-week cycle. In the dose-escalation phase...
Mukai, Yoichi Naito and Nobuaki Matsubara received research funding from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Glaxo SmithKline K.K., Nippon Boehringer Ingelheim Co
, AstraZeneca, Chugai Pharmaceutical, Bristol Myers Squibb, Merck Serono, Novartis Pharma, Merck Sharp & Dome, and J-Pharma. Nobuaki Matsubara has received research funds from Pfizer Japan Inc. Shigeyuki
SummaryTAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid tumors. This open-label, dose-escalation phase I study of TAS-115 consisted of three parts: part 1 (TAS-115 was...
, and to receiving meeting expenses from MDS; he also reported receiving meeting and medical writing financial support for this manuscript from Bayer Yakuhin Ltd., Tokyo, Japan. Nobuaki Matsubara reported
Background The biological basis for cancer of unknown primary (CUP) at the molecular level remains largely unknown, with no evidence of whether a common biological entity exists. Here, we assessed the possibility of identifying a common diagnostic biomarker for CUP using a microarray gene expression analysis. Methods Tumor mRNA samples from 60 patients with CUP were analyzed...
